COMMUNIQUÉS West-GlobeNewswire

Wave Life Sciences to Develop Programs in Rare, Genetic Eye Diseases
09/10/2018
Research will focus on inherited retinal diseases associated with RHO, USH2A, ABCA4 and CEP290 Initial development candidate expected in H2 2019 CAMBRIDGE, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd [...]
UPDATE - Aleafia to Launch Industry First 60,000 kg Secure Outdoor Grow Expansion
09/10/2018
Low Cost Expansion to Increase Aleafia’s Annual Production Capacity to 98,000 kg TORONTO, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Aleafia Health Inc. ( TSXV: ALEF; OTCQX: ALEAF, FRA: ARAH ) (“ Aleafia ”) or (the “ Company [...]
Myriad and Pfizer Build Upon a Previously Announced Companion Diagnostic Agreement
09/10/2018
Commercialization Plan Now in Place for BRACAnalysis CDx® As a Companion Diagnostic with Pfizer’s Talazoparib SALT LAKE CITY, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in [...]
Resonant Inc. to Introduce New 5G RF Filter Breakthrough at the 2018 IEEE International Ultrasonics Symposium in Kobe, Japan, on October 24th
09/10/2018
GOLETA, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for wireless devices, today announced [...]
IMV Inc. to Present at Upcoming Investor Conferences
09/10/2018
DARTMOUTH, Nova Scotia, Oct. 09, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that Chief Executive Officer Frederic Ors and Chief Financial [...]
Ziopharm and Precigen Redefine Relationships, Announce New License Agreement
09/10/2018
Ziopharm to Host Conference Call at 8 a.m. BOSTON and GERMANTOWN, Md., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) and Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation ( [...]
Radient Technologies Inc. receives Controlled Drugs and Substances Licence for its Manufacturing Facility
09/10/2018
EDMONTON, Alberta, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) ( TSX Venture: RTI ) is pleased to announce that it has received its Controlled Drugs and Substances Licence, [...]
Loxo Oncology Announces Details for Data Presentations at the European Society for Medical Oncology 2018 Congress
09/10/2018
STAMFORD, Conn., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, today announced that [...]
BriaCell Initiates Dosing in Phase I/IIa Combination Study with KEYTRUDA® or YERVOY®
09/10/2018
Patient dosing is underway in a combination study of Bria-IMT™ with KEYTRUDA ® (by Merck & Co., Inc.) or YERVOY ® (by Bristol-Myers Squibb Company) in advanced breast cancer. KEYTRUDA ® and YERVOY ® have been highly [...]
ASLAN Pharmaceuticals to Present Posters on Varlitinib and ASLAN003 at European Society for Medical Oncology Congress
09/10/2018
SINGAPORE, Oct. 09, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT, Nasdaq: ASLN), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan [...]
Canopy Rivers Announces Proposed Restructuring of Investment in TerrAscend
09/10/2018
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRES TORONTO, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Canopy Rivers Inc. (the “ Company ”) (TSXV: RIV) is pleased to announce it has entered into an arrangement [...]
Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the European Society for Medical Oncology 2018 Congress
09/10/2018
BERKELEY, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that data will be presented from its ongoing Phase 1b/2 study investigating SD-101, Dynavax's [...]
Transactions in relation to share buyback program
09/10/2018
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
A second abstract accepted at ISOBM in Hamburg demonstrating enhanced diagnostic value when using AroCell’s proprietary sample preparation method
09/10/2018
AroCell AB announces today that a second abstract has been accepted by ISOBM ( International Society of Oncology and BioMarkers) for poster presentation at the annual meeting in Hamburg, Germany November 24-27, 2018. [...]
CellaVision AB pesents the third quarter 2018 on October 23 at 11:00 CET
09/10/2018
CellaVision presents the third quarter 2018 on October 23 at 11:00 CET The information was submitted to the public on October 9, 2018 at 8:20 CET CellaVision AB (publ) will publish the interim report for the third [...]
Eurobio Scientific : 2018 MID-YEAR RESULTS
09/10/2018
2018 MID-YEAR RESULTS Significantly positive EBITDA at +€2.4M A first time in the Group History, thanks to the strategy implemented mid 2017 Paris, October 9, 2018 - 8.00 pm Eurobio Scientific (FR0013240934, ALERS, [...]
Eurobio Scientific : RESULTATS SEMESTRIELS 2018
09/10/2018
RESULTATS SEMESTRIELS 2018 EBITDA significativement positif à +2,4 M€ Une première dans l'histoire du Groupe, fruit de la stratégie mise en place mi 2017 Paris, le 9 octobre 2018 - 8h00 Eurobio Scientific (FR0013240934 [...]
Biocartis Group NV: DISCLOSURE OF OUTSTANDING VOTING SECURITIES
09/10/2018
PRESS RELEASE : REGULATED INFORMATION 9 October 2018, 07:00 CEST Disclosure of Outstanding Voting Securities Mechelen, Belgium, 9 October 2018 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular [...]
argenx awarded €2.6 million VLAIO grant to explore new applications of ABDEG technology
09/10/2018
October 9, 2018 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]

Pages